ClinicalTrials.gg
CompletedNCT05734807Updated Oct 15, 2024

A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia

A Phase 2 interventional study of Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs) and HH-003 and NrtIs in Chronic HBV Infection, sponsored by Huahui Health. Completed at 8 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Huahui Health · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jul 2022, registered Feb 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a multicenter, randomized, controlled Phase IIa study of HH-003 to evaluate the antiviral activity and safety in nucleos(t)ide analogues-treated chronic hepatitis B subjects with low-level viremia. HH-003 is a human monoclonal antibody targeting the pre-S1 domain of the HBV large envelope protein. It blocks engagement of preS1 with sodium taurocholate co-transporting polypeptide (NTCP), the cellular receptor for HBV.

02

Conditions studied

  • Chronic HBV Infection
03

In context

Lead sponsor

Huahui Health is the lead sponsor of 18 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form;
  • Male or female aged from 18 to 60 years (inclusively);
  • 18 kg/m\^2≤≤30 kg/m\^2, body weight≥50 kg for men and ≥45 kg for women;
  • Subjects who have chronic infection greater than or equal to 6 months at screening;
  • 10 IU/mL≤HBsAg≤3000 IU/mL; HBV DNA≤2000 IU/mL; ≤3×;
  • Subjects who have been on nucleoside reverse transcriptase inhibitors therapy for more than 1 year prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant or lactating at screening;
  • History of alcoholic liver disease, moderate fatty liver, liver disease, other hereditary liver disease, drug-induced liver disease or other chronic liver disease induced by non- infection;
  • History of cirrhosis at any time prior to or at time of screening, or having progressive liver fibrosis at screening ;
  • History or evidence of hepatocellular carcinoma at any time prior to or at time of screening;
  • Exclusionary laboratory results at screening: total >2xULN or direct bilirubin >1.5xULN, \<120 g/L for males or \<110 g/L ro females, count\<100,000/mm\^3 (100×10\^9/L), and absolute neutrophils count \<1,500/mm\^3 (1.5×10\^9/L).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Active comparator
    NrtIs

    Drug: Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)

  • Experimental
    HH-003+NrtIs

    Drug: HH-003 and NrtIs

  • Experimental
    HH-003+NrtIs+PEG-IFN-α

    Drug: HH-003, NrtIs and PEG-IFN-α

Interventions

  • DrugNucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)

    Subjects will receive NrtIs therapy for 24 weeks.

  • DrugHH-003 and NrtIs

    Drug page: Libevitug

    Subjects will receive HH-003 20 mg/kg intravenously Q2W and NrtIs therapy for 24 weeks.

  • DrugHH-003, NrtIs and PEG-IFN-α

    Subjects will receive HH-003 20 mg/kg intravenously Q2W, NrtIs therapy and PEG-IFN-α 180μg SC QW for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with HBV DNA negativation

    Time frame: Week 24

  2. Changes from baseline in serum HBsAg

    Time frame: From treatment start up to Week 48

Secondary outcomes

  1. Percentage of subjects achieving maintained virologic response (MVR)

    Time frame: From treatment start up to 48 weeks

  2. Duration of MVR

    Time frame: From treatment start up to 48 weeks

  3. Percentage of subjects with ALT normalization

    Time frame: From treatment start up to 48 weeks

  4. Changes from baseline in serum HBeAg in subjects with positive HBeAg

    Time frame: From treatment start up to 48 weeks

07

Study locations

8 sites
  • Beijing Ditan Hospital,Capital Medical University
    Beijing, Beijing 100015, China
  • Beijing Friendship Hospital,Capital Medical University
    Beijing, Beijing 100050, China
  • Beijing Youan Hospital,Capital Medical University
    Beijing, Beijing 100069, China
  • Mengchao Hepatobiliary Hospital Of Fujian Medical University
    Fuzhou, Fujian 350025, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • The Sixth Peoples Hospital Of Zhengzhou
    Zhengzhou, Henan 450006, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130061, China
  • Shandong Public Health Clinical Center
    Jinan, Shandong 250102, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Apr 2024, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2023
First posted
Feb 21, 2023
StartActual
Jul 20, 2022
Primary completionActual
Apr 17, 2024
CompletionActual
Apr 17, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05734807
Lead sponsor
Huahui Health
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
Jul 20, 2022
Primary completion
Apr 17, 2024
Completion
Apr 17, 2024
Last update
Oct 15, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Libevitug

Start the discussion